Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Bayer AG

Agricultural Conglomerate Bayer Confident In Long-Term Outlook Despite Litigation Risks

On Wednesday, Bayer AG (OTC:BAYRY) reported adjusted earnings of 17 cents per ADS (57 cents in euros), up from 7 cents a year ago (24 cents euros).

The French rebel against a pesticide authorised for use in the European Union

The French rebel against a pesticide authorised for use in the European Union

The Duplomb Law is being fiercely contested by civil society and a petition opposes the reintroduction of a pesticide.

Bayer Hit with $100 Million Verdict Over Toxic PCB Exposure

Bayer Hit with $100 Million Verdict Over Toxic PCB Exposure

Bayer AG faces a $100 million jury verdict over PCB exposure at a Seattle school amid ongoing legal challenges related to toxic chemicals.

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Middle East Conflict Threatens Israeli Agriculture Giants’ Operations

Tensions between Israel and Hamas put Bayer, Deere, and Cargill investments at risk

Chronic pelvic pain affects up to 26% of women – our latest research brings us closer to better treating it

Chronic pelvic pain affects between 5% and 26% of women worldwide. It can be associated with conditions such as endometriosis (where tissue resembling the lining of the womb is found outside the womb) and interstitial cystitis (bladder pain syndrome). Some women also have chronic pelvic pain without a specific cause.

The Conversation

US judge yanks approval for Idaho mine after finding that federal agency violated environmental laws

A federal judge has yanked the U.S. government's approval for a phosphate mining project in southeastern Idaho

The Independent UK

Regeneron, Bayer offer more promising data for aging eye drug

Bayer AG and Regeneron Pharmaceuticals Inc.’s blockbuster eye drug reached another clinical milestone by showing sustained efficacy in trials that could help the companies push back against a competing product from Roche Holding AG.

Tribune News Service

inkl

Read news from The Economist, FT, and more,
with one subscription

3 Cheap Large-Cap Stocks Still Beating the Market

3 Cheap Large-Cap Stocks Still Beating the Market

With job growth remaining strong in June, the Fed is expected to raise interest rates aggressively. Therefore, the stock market may witness further downside. Amid this backdrop, it could be wise to invest in large-cap stocks Bristol-Myers Squibb (BMY), Bayer (BAYRY), and Mitsubishi Heavy Industries (MHVYF), which have shown resilience…

5 Buy-Rated Healthcare Stocks Trading at a Discount

5 Buy-Rated Healthcare Stocks Trading at a Discount

Inelastic demand, growing investments, and impressive breakthroughs should help the healthcare sector survive the potential recession. This is why we believe quality healthcare stocks Assertio (ASRT), Bayer (BAYRY), Bristol-Myers Squibb (BMY), Catalyst Pharmaceuticals (CPRX), and Ipsen (IPSEY), which are currently trading at discounts to their peers, could be solid investments…

BWXT Medical, Bayer Ink Commercial Agreement For Actinium-225 Based Products

BWXT Medical, Bayer Ink Commercial Agreement For Actinium-225 Based Products

BWX Technologies Inc (NYSE:BWXT) subsidiary BWXT Medical Ltd. has entered a commercial agreement with Bayer AG (OTC:BAYRY) to supply high-purity Actinium-225 (Ac-225). Bayer will purchase high-purity Ac-225 from BWXT Medical at pre-determined prices. The parties expect supply to commence later this year. The above agreement follows the agreement reached by the parties in September 2021.…

Read Why Did HC Wainwright Cut Price Target On Atara Biotherapeutics

Read Why Did HC Wainwright Cut Price Target On Atara Biotherapeutics

Late last week, Atara Biotherapeutics Inc (NASDAQ:ATRA) announced that Bayer AG (OTC:BAYRY) intends to terminate the exclusive worldwide licensing agreement for Atara's mesothelin-targeted allogeneic and autologous CAR-T assets, ATA3271 and ATA2271. The enrollment was paused in the Phase 1 trial of ATA2271 for mesothelioma after a patient death. The move followed a strategic review and asset-level prioritization.…

Bayer Intends To Bow Out From CAR-T Therapy Pact With Atara

Bayer Intends To Bow Out From CAR-T Therapy Pact With Atara

Atara Biotherapeutics Inc (NASDAQ:ATRA) received notification that Bayer AG's (OTC:BAYRY) intends to end the exclusive worldwide licensing agreement for mesothelin-directed CAR T-cell therapies. The collaboration included the funding and development of ATA3271, allogeneic T-cell immunotherapy, and an autologous version, ATA2271, for high mesothelin-expressing tumors. ATA3271 leverages Atara's EBV T-cell platform and is currently in IND…

Why Are Evotec Shares Trading Lower On Friday?

Why Are Evotec Shares Trading Lower On Friday?

Bayer AG (OTC: BAYRY) has

People

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

US Federal Reserve

the National Assembly

BristolMyers Squibb Company

the Center for Biological Diversity

Regeneron Pharmaceuticals Inc

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Multiple Sclerosis

Places

345,861 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play